BURDEN OF BRAIN METASTASES (BM) IN ALK plus NON-SMALL CELL LUNG CANCER (ALK plus NSCLC) TREATED WITH FIRST-LINE ALK INHIBITORS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW (SLR)

被引：0
|
作者：
Pan, X. [1 ]
Kwon, C. S. [2 ]
Garib, S. A. [2 ]
Forsythe, A. [2 ]
Lin, H. M. [1 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
[2] Purple Squirrel Econ, New York, NY USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN22
引用
收藏
页码：S439 / S439
页数：1
相关论文
共 50 条
  • [41] Efficacy of ALK Inhibitors in the Treatment of ALK-rearranged Non-small Cell Lung Cancer and Brain Metastases: A Meta-analysis
    Luo, P.
    Fan, J.
    Zou, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2373 - S2373
  • [42] Genomic heterogeneity of ALK rearrangements and acquired resistance pathways in ALK plus Advanced non-small cell lung cancer (NSCLC) treated with upfront alectinib: Preliminary results of GALILEO project
    Vita, E.
    Monaca, F.
    Russo, J.
    Stefani, A.
    Zhang, Q.
    Di Salvatore, M.
    Trisolini, R.
    Lococo, F.
    Cancellieri, A.
    Tortora, G.
    Bria, E.
    ANNALS OF ONCOLOGY, 2023, 34
  • [43] Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
    Barrows, Stephanie M.
    Wright, Kelly
    Copley-Merriman, Catherine
    Kaye, James A.
    Chioda, Marc
    Wiltshire, Robin
    Torgersen, Knut Martin
    Masters, Elizabeth T.
    LUNG CANCER-TARGETS AND THERAPY, 2019, 10 : 11 - 20
  • [44] Background of patients (pts) with ALK rearranged (ALK plus ) non-small-cell lung cancer (NSCLC), and efficacy and safety of ALK inhibitors (ALK-Is) in actual clinical practice: Multicenter retrospective study
    Ito, K.
    Saiki, H.
    Sakaguchi, T.
    Hayashi, K.
    Nishii, Y.
    Watanabe, F.
    Hataji, O.
    Okano, T.
    Naito, M.
    Ibata, H.
    Fujiwara, A.
    Yoshida, M.
    Itani, H.
    Tanigawa, M.
    Kobayashi, H.
    ANNALS OF ONCOLOGY, 2015, 26 : 140 - 140
  • [45] Evaluation of Toxicity Profile of ALK Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
    Hong, S.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2392 - S2392
  • [46] Resistance mechanisms and efficacy of first-line (1L) alectinib in patients (pts) with ALK-rearranged non-small cell lung cancer (ALK plus NSCLC): Second interim analysis of ALCURE
    Mouri, A.
    Tsuda, T.
    Oki, M.
    Ichihara, E.
    Tanaka, H.
    Azuma, K.
    Arai, R.
    Kuyama, S.
    Akamatsu, H.
    Otsubo, K.
    Ajimizu, H.
    Matsumoto, M.
    Seto, Y.
    Uchibori, K.
    Hayashi, H.
    Miyauchi, E.
    Ishizuka, N.
    Kajihara, Y.
    Nakagawa, Y.
    Katayama, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S1644 - S1645
  • [47] Anti-ALK autoantibodies in patients with ALK positive non-small cell lung cancer (NSCLC)
    Parisi, C.
    Benitez, J. C.
    Lecourt, H.
    Dall'Olio, F. G.
    Aldea, M.
    Blanc-Durand, F.
    Verge, V.
    Quivoron, C.
    Naltet, C.
    Abdayem, P.
    Lavaud, P.
    Ghigna, M. R.
    Loriot, Y.
    De Botton, S.
    Planchard, D.
    Barlesi, F.
    Soria, J-C.
    Ribrag, V.
    Friboulet, L.
    Besse, B.
    ANNALS OF ONCOLOGY, 2021, 32 : S956 - S957
  • [48] Clinical benefit from pemetrexed before and after crizotinib exposure in patients with ALK positive non-small cell lung cancer (ALK plus NSCLC).
    Berge, Eamon
    Delee, Maxon
    Lu, Xian
    Baron, Anna E.
    Solomon, Benjamin J.
    Doebele, Robert Charles
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Efficacy and Safety of ALK Inhibitors in ALK-Rearranged Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Breadner, D.
    Shanmuganatjan, S.
    Boldt, G.
    Blanchette, P.
    Raphael, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1034 - S1034
  • [50] A TARGETED LITERATURE REVIEW ON ALK plus NON-SMALL CELL LUNG CANCER (NSCLC) EPIDEMIOLOGY, DIAGNOSTICS, AND ECONOMIC OUTCOMES RELEVANT TO LATIN AMERICA
    Balu, Sanjeev
    Sesena Carrillo, Lucia
    Solon, Caroline
    Forman, Sarah
    Camacho, Oscar
    Duttagupta, Sandeep
    Angeletti, Francesca
    Beckerman, Rachel
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S159 - S159
12345